Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b Patients

Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Population Shows Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b PatientsMonday, February 22, 2016 6:59 am EST  "This is an important finding because the burden of HCV in China is extremely high, and newer direct-acting antivirals have yet to be introduced for any patients."PRINCETON, N.J.--(BUSIN

FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Updated label provides new treatment option for patients with HIV-1 coinfection, advanced cirrhosis, and post-liver transplant HCV recurrenceFriday, February 5, 2016 12:47 pm EST--PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza™ (daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) in combination with sofosbuvir (with or without r

Daclatasvir coming to a pharmacy near you soon?

August 20, 2015:  Today we received news that another upcoming drug, daclatasvir (Daklinza™) from Bristol-Myers Squibb, has received a Notice of Compliance from Health Canada. It is already being considered for coverage by British Columbia's Pharmacare, though it has not yet been approved. This drug is unique in its potential to mix and match with other drugs in order to treat a variety of genotypes, including hard-to-treat genotype 3 (combined with Gilead

Summer of Interferon-free Hepatitis C Drug Approvals?

2015 is stacking up to have a Summer of Interferon-Free hepatitis C drug approvals! So far we've had the following approvals for provincial Pharmacare coverage (addition to provincial "formulary"):On June 29th, Ontario covered AbbVie's Holkira Pak™ for genotype 1, on July 24th, Quebec covered both Gilead's Harvoni™ and AbbVie's Holkira Pak™ for genotype 1. And on World Hepatitis Day, July 28th British Columbia, Saskatchewan, Manitoba, and Yukon started to ...

Bristol-Myers Squibb’s “Stand-Alone” marketing of daclatasvir worldwide refreshing change

Amadou Diarra, Bristol-Myers Squibb Vice President, Global Policy & Government Affairs, source BMS website We recently praised the Bristol-Myers Squibb (BMS) marketing of daclatasvir as a 'stand-alone' hepatitis C drug which could be easily marketed and combined with other drugs instead of being packaged only with other drugs from the same company in a proprietary "package" (http://hepcbc.ca/2014/10/praise-stand-alone-hcv-drugs/). When our goal is th

In Praise of Stand-Alone HCV Drugs

BMS recently withdrew its US FDA application for the hepatitis C drug, asunaprevir. It is probably a very wise decision on BMS' part, because asunaprevir is close in formulation and results to several other generation 2 NS3 protease inhibitors*. Instead, BMS seems to be focusing on its more unique product, the NS5A replication complex inhibitor, daclatasvir, of which they say in their Oct. 7 press release, is "currently being investigated globally in multi